118 related articles for article (PubMed ID: 36633637)
1. Re-induction therapy in patients with acute myeloid leukemia not in complete remission after the first course of treatment.
Fu W; Hu Y; Lu G; Xu L; Gao L; Chen J; Chen L; Tang G; Ni X; Yang J
Ann Hematol; 2023 Feb; 102(2):329-335. PubMed ID: 36633637
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of high-dose cytarabine and aclarubicin in combination with G-CSF regimen compared to intermediate/high-dose cytarabine and standard-dose cytarabine induction regimen for non-remission acute myeloid leukemia.
Lei M; Liu L; Wang Z; Wu D
Indian J Cancer; 2019; 56(2):167-172. PubMed ID: 31062738
[TBL] [Abstract][Full Text] [Related]
3. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia.
Fleischmann M; Schnetzke U; Frietsch JJ; Sayer HG; Schrenk K; Hammersen J; Glaser A; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2022 Jun; 148(6):1481-1492. PubMed ID: 34297206
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy Comparison of Different Salvage Treatment Regimens for Patients with Refractory/Relapsed Acute Myeloid Leukemia].
Gao WH; Li HM; Yu JY; Zheng YL; Wu LH; Liu QG; Li JF; Liu CH; Hu YM; Xu N; Li SZ; Mi YC; Huang PP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):340-345. PubMed ID: 28446272
[TBL] [Abstract][Full Text] [Related]
5. Standard-Intensity Induction and Intermediate/High-Dose Cytarabine Consolidation Can Improve Survival for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: A Retrospective Cohort Study.
Wang L; Zhao N; Zhou L; Tong J; Xue L; Zhang L; Han Y; Wang X; Geng L; Tang B; Liu H; Zhu W; Cai X; Liu X; Zhu X; Sun Z; Zheng C
Clin Interv Aging; 2022; 17():55-64. PubMed ID: 35082491
[TBL] [Abstract][Full Text] [Related]
6. Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia: a prospective cohort study.
Bao Y; Zhao J; Li ZZ
Clin Transl Oncol; 2018 Jul; 20(7):870-880. PubMed ID: 29181696
[TBL] [Abstract][Full Text] [Related]
7. Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapy.
Zhu HH; Jiang H; Jiang B; Lu J; Jiang Q; Bao L; Zhang XH; Qin YZ; Huang XJ
Leuk Lymphoma; 2013 Nov; 54(11):2452-7. PubMed ID: 23432721
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of the efficacy of IA and HAD induction regimens in the treatment of patients with newly diagnosed acute myeloid leukemia: a single-center study].
Zhang CX; Qiu SW; Gong BF; Gong XY; Li Y; Liu YT; Fang QY; Zhang GJ; Liu KQ; Zhou CL; Wei SN; Lin D; Liu BC; Wang Y; Mi YC; Wei H; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2022 May; 43(5):383-387. PubMed ID: 35680595
[No Abstract] [Full Text] [Related]
9. Re-induction with modified CLAG regimen in relapsed or refractory acute myeloid leukemia in children bridging to allogeneic hematopoietic stem cell transplantation.
Zhang N; Shao JB; Li H; Yang JW; Chen K; Zhu JS; Jiang H
World J Pediatr; 2020 Apr; 16(2):152-158. PubMed ID: 31748985
[TBL] [Abstract][Full Text] [Related]
10. [Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].
Qin T; Xu Z; Zhang Y; Lin Y; Ru K; Fang L; Zhang H; Pan L; Hu N; Qu S; Wang J; Xing R; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):94-9. PubMed ID: 27014976
[TBL] [Abstract][Full Text] [Related]
11. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and feasibility of cyclophosphamide combined with intermediate- dose or high-dose cytarabine for relapsed and refractory acute myeloid leukemia (AML).
Schnetzke U; Fix P; Spies-Weisshart B; Schrenk K; Glaser A; Fricke HJ; La Rosée P; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2014 Aug; 140(8):1391-7. PubMed ID: 24728467
[TBL] [Abstract][Full Text] [Related]
13. [The Impact of Induction Treatment Response on the Prognosis of Pediatric Core Binding Factor-Acute Myeloid Leukemia Patients].
Zeng HM; Hu GH; Lu AD; Jia YP; Zuo YX; Wu J; Zhang LP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Feb; 29(1):56-61. PubMed ID: 33554797
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
[TBL] [Abstract][Full Text] [Related]
15. [A long-term follow-up study of 82 children with acute myeloid leukemia].
Ruan M; Qi BQ; Liu F; Liu TF; Liu XM; Chen XJ; Yang WY; Guo Y; Zhang L; Zou Y; Chen YM; Zhu XF
Zhonghua Er Ke Za Zhi; 2018 Oct; 56(10):730-734. PubMed ID: 30293275
[No Abstract] [Full Text] [Related]
16. [Clinical Efficacy and Survival Analysis of Adult Patients with Acute Myeloid Leukemia after Microtransplantation].
Huang YJ; Zhang JH; Dong CX; Kang JM; Hou YF; Zhang YF; Qi K; Yang LH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1361-1368. PubMed ID: 36208236
[TBL] [Abstract][Full Text] [Related]
17. Effective salvage therapy for high-risk relapsed or refractory acute myeloid leukaemia with cisplatin in combination with high-dose cytarabine and etoposide.
Lee YG; Kwon JH; Kim I; Yoon SS; Lee JS; Park S
Eur J Haematol; 2014 Jun; 92(6):478-84. PubMed ID: 24460733
[TBL] [Abstract][Full Text] [Related]
18. Homoharringtonine, aclarubicin and cytarabine (HAA) regimen as the first course of induction therapy is highly effective for acute myeloid leukemia with t (8;21).
Zhu HH; Jiang H; Jiang Q; Jia JS; Qin YZ; Huang XJ
Leuk Res; 2016 May; 44():40-4. PubMed ID: 26994850
[TBL] [Abstract][Full Text] [Related]
19. The outcome and prognostic factors of 248 elderly patients with acute myeloid leukemia treated with standard-dose or low-intensity induction therapy.
Chen Y; Yang T; Zheng X; Yang X; Zheng Z; Zheng J; Liu T; Hu J
Medicine (Baltimore); 2016 Jul; 95(30):e4182. PubMed ID: 27472687
[TBL] [Abstract][Full Text] [Related]
20. A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG).
Wrzesień-Kuś A; Robak T; Lech-Marańda E; Wierzbowska A; Dmoszyńska A; Kowal M; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S; Maj S; Hellmann A; Skotnicki A; Jedrzejczak W; Kuliczkowski K;
Eur J Haematol; 2003 Sep; 71(3):155-62. PubMed ID: 12930315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
